{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:19Z","timestamp":1772166439804,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2018-00964"],"award-info":[{"award-number":["2018-00964"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["2020-1107"],"award-info":[{"award-number":["2020-1107"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-02226"],"award-info":[{"award-number":["2022-02226"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The results of germline genetic testing for hereditary cancer are of importance not only to the patients under investigation but also to their genetic at-risk relatives. Standard care is to encourage the proband (first family member under investigation) to pass on this risk information to the relatives. Previous research suggests that with family-mediated disclosure, only about a third of at-risk relatives contact health care to receive genetic counselling. In some studies, complementing family-mediated risk disclosure with healthcare-assisted risk disclosure almost doubles the uptake of genetic counselling in at-risk relatives. In this study, we evaluate healthcare-assisted direct letters to relatives at risk of hereditary cancer syndromes in a randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Probands are recruited from Swedish outpatient cancer genetics clinics to this two-arm randomized controlled trial. The study recruits probands with either a pathogenic variant in a cancer susceptibility gene (\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ,\n                      <jats:italic>BRCA2<\/jats:italic>\n                      ,\n                      <jats:italic>PALB2<\/jats:italic>\n                      ,\n                      <jats:italic>MLH1<\/jats:italic>\n                      ,\n                      <jats:italic>MSH2<\/jats:italic>\n                      ,\n                      <jats:italic>MSH6<\/jats:italic>\n                      ,\n                      <jats:italic>PMS2<\/jats:italic>\n                      ) or probands with familial breast and colorectal cancer based on clinical and pedigree criteria. In both arms, probands receive standard care, i.e., are encouraged and supported to pass on information to relatives. In the intervention arm, the proband is also offered to have direct letters sent to the at-risk relatives. The primary outcome measure is the proportion of at-risk relatives contacting a Swedish cancer genetics clinic within 12\u00a0months of the proband receiving the test results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This paper describes the protocol of a randomized controlled clinical trial evaluating a healthcare-assisted approach to risk disclosure by offering the probands to send direct letters to their at-risk relatives. The results of this study should be informative in the future development of risk disclosure practices in cancer genetics clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov. Identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04197856?id=NCT04197856&amp;draw=2&amp;rank=1&amp;load=cart\">NCT04197856<\/jats:ext-link>\n                      (pre-trial registration on December 13, 2019).\n                    <\/jats:p>\n                    <jats:p>Also registered at the website \u201cRCC Cancerstudier i Sverige\u201d as study #86719.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07829-5","type":"journal-article","created":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T08:02:18Z","timestamp":1702800138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Direct letters to relatives at risk of hereditary cancer\u2014study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study)"],"prefix":"10.1186","volume":"24","author":[{"given":"Carolina","family":"Hawranek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Ehrencrona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"\u00d6fverholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbro Numan","family":"Hellquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2441-2395","authenticated-orcid":false,"given":"Anna","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,17]]},"reference":[{"key":"7829_CR1","unstructured":"The DIRECT study. Available from: https:\/\/www.umu.se\/direct. Accessed 20 Aug 2023."},{"issue":"5","key":"7829_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/bjs.11902","volume":"108","author":"TT Seppala","year":"2021","unstructured":"Seppala TT, Latchford A, Negoi I, Sampaio Soares A, Jimenez-Rodriguez R, Sanchez-Guillen L, et al. European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. Br J Surg. 2021;108(5):484\u201398.","journal-title":"Br J Surg"},{"issue":"3","key":"7829_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/gutjnl-2019-319915","volume":"69","author":"KJ Monahan","year":"2020","unstructured":"Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop MG, East JE, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)\/Association of Coloproctology of Great Britain and Ireland (ACPGBI)\/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69(3):411\u201344.","journal-title":"Gut"},{"issue":"1","key":"7829_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balmana J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023;34(1):33\u201347.","journal-title":"Ann Oncol"},{"issue":"10","key":"7829_CR5","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/gim.2017.244","volume":"20","author":"M Di Marco","year":"2018","unstructured":"Di Marco M, D\u2019Andrea E, Panic N, Baccolini V, Migliara G, Marzuillo C, et al. Which Lynch syndrome screening programs could be implemented in the \u201creal world\u201d? A systematic review of economic evaluations. Genet Med. 2018;20(10):1131\u201344.","journal-title":"Genet Med"},{"issue":"35","key":"7829_CR6","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1200\/JCO.22.00303","volume":"40","author":"MK Frey","year":"2022","unstructured":"Frey MK, Ahsan MD, Bergeron H, Lin J, Li X, Fowlkes RK, et al. Cascade testing for hereditary cancer syndromes: should we move toward direct relative contact? A systematic review and meta-analysis. J Clin Oncol. 2022;40(35):4129\u201343.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7829_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/ejhg.2015.174","volume":"24","author":"A Mendes","year":"2016","unstructured":"Mendes A, Paneque M, Sousa L, Clarke A, Sequeiros J. How communication of genetic information within the family is addressed in genetic counselling: a systematic review of research evidence. Eur J Hum Genet. 2016;24(3):315\u201325.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"7829_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10689-018-0083-5","volume":"18","author":"HV Petersen","year":"2019","unstructured":"Petersen HV, Frederiksen BL, Lautrup CK, Lindberg LJ, Ladelund S, Nilbert M. Unsolicited information letters to increase awareness of Lynch syndrome and familial colorectal cancer: reactions and attitudes. Fam Cancer. 2019;18(1):43\u201351.","journal-title":"Fam Cancer"},{"issue":"1","key":"7829_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/jnci\/djy147","volume":"111","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW. Cascade genetic testing of relatives for hereditary cancer risk: results of an online initiative. J Natl Cancer Inst. 2018;111(1):95\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"7829_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.19.02005","volume":"38","author":"MK Frey","year":"2020","unstructured":"Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires M, Christos P, et al. Prospective feasibility trial of a novel strategy of facilitated cascade genetic testing using telephone counseling. J Clin Oncol. 2020;38(13):1389\u201397.","journal-title":"J Clin Oncol"},{"issue":"3","key":"7829_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/medethics-2015-102781","volume":"42","author":"S Dheensa","year":"2016","unstructured":"Dheensa S, Fenwick A, Lucassen A. \u2018Is this knowledge mine and nobody else\u2019s? I don\u2019t feel that.\u2019 Patient views about consent, confidentiality and information-sharing in genetic medicine. J Med Ethics. 2016;42(3):174\u20139.","journal-title":"J Med Ethics"},{"issue":"6","key":"7829_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/jpm11060538","volume":"11","author":"NB Henrikson","year":"2021","unstructured":"Henrikson NB, Blasi P, Gray M, Tiffany BT, Scrol A, Ralston JD, et al. Patient and family preferences on health system-led direct contact for cascade screening. J Pers Med. 2021;11(6):538.","journal-title":"J Pers Med"},{"issue":"8","key":"7829_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/jpm12081249","volume":"12","author":"C Pedrazzani","year":"2022","unstructured":"Pedrazzani C, Aceti M, Schweighoffer R, Kaiser-Grolimund A, B\u00fcrki N, Chappuis PO, et al. The communication chain of genetic risk: analyses of narrative data exploring proband\u2013provider and proband\u2013family communication in hereditary breast and ovarian cancer. J Pers Med. 2022;12(8):1249.","journal-title":"J Pers Med"},{"key":"7829_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13053-020-00151-0","volume":"18","author":"A Andersson","year":"2020","unstructured":"Andersson A, Hawranek C, Ofverholm A, Ehrencrona H, Grill K, Hajdarevic S, et al. Public support for healthcare-mediated disclosure of hereditary cancer risk information: results from a population-based survey in Sweden. Hered Cancer Clin Pract. 2020;18:18.","journal-title":"Hered Cancer Clin Pract"},{"issue":"11","key":"7829_CR15","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/jpm11111191","volume":"11","author":"C Hawranek","year":"2021","unstructured":"Hawranek C, Hajdarevic S, Rosen A. A focus group study of perceptions of genetic risk disclosure in members of the public in Sweden: \u201cI\u2019ll phone the five closest ones, but what happens to the other ten?\u201d J Pers Med. 2021;11(11):1191.","journal-title":"J Pers Med"},{"key":"7829_CR16","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1136\/medethics-2020-106236","volume":"47","author":"K Grill","year":"2021","unstructured":"Grill K, Rosen A. Healthcare professionals\u2019 responsibility for informing relatives at risk of hereditary disease. J Med Ethics. 2021;47:e12.","journal-title":"J Med Ethics"},{"issue":"1","key":"7829_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41431-022-01200-z","volume":"31","author":"AL Young","year":"2023","unstructured":"Young AL, Imran A, Spoelma MJ, Williams R, Tucker KM, Halliday J, et al. Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review. Eur J Hum Genet. 2023;31(1):18\u201334.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"7829_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/GIM.0b013e318164540b","volume":"10","author":"LE Forrest","year":"2008","unstructured":"Forrest LE, Burke J, Bacic S, Amor DJ. Increased genetic counseling support improves communication of genetic information in families. Genet Med. 2008;10(3):167\u201372.","journal-title":"Genet Med"},{"issue":"1","key":"7829_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s40814-022-01142-9","volume":"8","author":"PR Blasi","year":"2022","unstructured":"Blasi PR, Scrol A, Anderson ML, Gray MF, Tiffany B, Fullerton SM, et al. Feasibility, acceptability, and limited efficacy of health system-led familial risk notification: protocol for a mixed-methods evaluation. Pilot Feasibility Stud. 2022;8(1):174.","journal-title":"Pilot Feasibility Stud"},{"key":"7829_CR20","volume-title":"The State-Trait Anxiety Inventory (\u201cSelf-evaluation questionnaire\u201d)","author":"CD Spielberger","year":"1970","unstructured":"Spielberger CD, Gorsuch RL, Lushene RE. The State-Trait Anxiety Inventory (\u201cSelf-evaluation questionnaire\u201d). Palo Alto: Consulting Psychologist Press; 1970."},{"key":"7829_CR21","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1002\/pon.4782","volume":"27","author":"JAE Custers","year":"2018","unstructured":"Custers JAE, Kwakkenbos L, van de Wal M, Prins JB, Thewes B. Re-validation and screening capacity of the 6-item version of the Cancer Worry Scale. Psychooncology. 2018;27:2609\u201315.","journal-title":"Psychooncology"},{"issue":"4","key":"7829_CR22","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3390\/cancers14040918","volume":"14","author":"C Hawranek","year":"2022","unstructured":"Hawranek C, Maxon J, Andersson A, Van Guelpen B, Hajdarevic S, NumanHellquist B, et al. Cancer worry distribution and willingness to undergo colonoscopy at three levels of hypothetical cancer risk-a population-based survey in Sweden. Cancers (Basel). 2022;14(4):918.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"7829_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00449430","volume":"2","author":"C Forsberg","year":"1993","unstructured":"Forsberg C, Bjorvell H. Swedish population norms for the GHRI, HI and STAI-state. Qual Life Res. 1993;2(5):349\u201356.","journal-title":"Qual Life Res"},{"issue":"1","key":"7829_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s41687-021-00331-z","volume":"5","author":"E Ohlsson-Nevo","year":"2021","unstructured":"Ohlsson-Nevo E, Hiyoshi A, Noren P, Moller M, Karlsson J. The Swedish RAND-36: psychometric characteristics and reference data from the Mid-Swed Health Survey. J Patient Rep Outcomes. 2021;5(1):66.","journal-title":"J Patient Rep Outcomes"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07829-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07829-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07829-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T08:02:45Z","timestamp":1702800165000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07829-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,17]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7829"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07829-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2723143\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,17]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol and amendments have been approved by the Swedish Ethical review authority.Dnr 2019-02647, approved 2019 June 19. Amendments: Dnr 2020-01176, approved 2020 May 18, Dnr 2021-00718, approved 2021 March 11, and Dnr 2021-05890, approved 2021 December 15.All patients participating in the study receive written and oral information before signing an informed consent to participate. The participant information and informed consent form, translated into English, are found in the\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"N.A. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"810"}}